T2 Biosystems to Present at the 37th Annual Canaccord Genuity Growth Conference
August 02 2017 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced that John McDonough, president and chief
executive officer, and Darlene Deptula-Hicks, SVP and chief
financial officer, are scheduled to attend and present at the 37th
Annual Canaccord Genuity Growth Conference. The conference is being
held August 9-10, 2017 at the InterContinental Hotel in Boston, MA.
Management is scheduled to present on Wednesday, August 9, 2017
at 11:00 a.m. ET and will be available for one-on-one meetings
during the conference. The presentation will be webcast live
and available for replay and may be accessed by visiting the
Investors/Events & Presentations section of the Company’s
website at www.t2biosystems.com. A replay of the
webcast will be available shortly after the conclusion of the
presentation and will be archived on the Company's website for 90
days following the presentation.
About T2 Biosystems T2 Biosystems is
dedicated to developing innovative diagnostic products to improve
patient health. With the FDA-cleared T2Dx® Instrument and
T2Candida® Panel targeting sepsis and a range of additional
products in development, T2 Biosystems is an emerging
leader in the field of in vitro diagnostics. The Company is
utilizing its proprietary T2 Magnetic Resonance technology, or
T2MR®, to develop a broad set of applications aimed at lowering
mortality rates, improving patient outcomes and reducing the cost
of healthcare by helping medical professionals make targeted
treatment decisions earlier. T2MR enables the fast and sensitive
detection of pathogens, biomarkers and other abnormalities in a
variety of patient sample types, including whole blood. For more
information, please
visit www.t2biosystems.com.
Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803
Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466
Investor Contact:
Chris Brinzey, Westwicke Partners
chris.brinzey@westwicke.com
339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024